<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00875888</url>
  </required_header>
  <id_info>
    <org_study_id>0000050</org_study_id>
    <secondary_id>ISRCTN77656437</secondary_id>
    <nct_id>NCT00875888</nct_id>
  </id_info>
  <brief_title>High Cut-Off Continuous Veno-venous Hemodialysis (CVVHD) in Patients Treated for Acute Renal Failure After Systemic Inflammatory Response Syndrome (SIRS)/Septic Shock</brief_title>
  <acronym>HICOSS</acronym>
  <official_title>High Cut-off Continuous Venovenous Hemodialysis (CVVHD) to Improve Hemodynamic Stability and Organ Function Scores in Patients Treated for Acute Renal Failure After Systemic Inflammatory Response Syndrome (SIRS)/Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gambro Dialysatoren GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Baxter Healthcare Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the influence of the High Cut-Off (HCO) CVVHD treatment on the disease
      progression in septic patients. The primary aim of the study is to evaluate whether HCO CVVHD
      leads to a significant improvement of the hemodynamic status (mean arterial pressure,
      vasopressor requirements) in septic patients in comparison to CVVHD treatment with
      conventional high-flux filters. For the HCO-group the investigators expect a 50% lower dosage
      of vasopressors needed to maintain an adequate organ perfusion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Severe sepsis is a devastating disorder that results from a complex host response to insult
      after infection. Despite advances in intensive care technologies sepsis remains an important
      and life-threatening problem. Sepsis is the most common cause of death in the intensive care
      unit.

      Local or systemic release of bacteria-derived compounds, leading to the production of
      proinflammatory cytokines, induce systemic inflammatory reactions in septic patients.
      Continuous renal replacement therapies (CRRT) such as hemodialysis (CVVHD), hemofiltration
      (CVVH) or hemodiafiltration (CVVHDF) with conventional high-flux membranes allow to control
      fluid and electrolyte balance, and to improve the hemodynamic status of the patients.
      However, conventional high flux membranes have a limited permeability for sepsis-associated
      mediators with molecular weights in the range of 15.000 to 60.000 Da.

      A promising approach to enhance the mediator removal is to use membranes having larger pores
      and permeability characteristics than those currently used in CRRT.

      For that purpose a High Cut-Off (HCO) membrane has been developed and is manufactured by
      Gambro Research.After demonstrating the safety as well as the cytokine removal effectiveness
      in a clinical pilot study this study will assess the influence of the HCO treatment on the
      disease progression in septic patients.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    based on interim analysis statistical significance in primary endpoint cannot be achieved with
    planned sample size, no safety concerns
  </why_stopped>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dosage of vasopressors</measure>
    <time_frame>day 1 to day 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean arterial pressure</measure>
    <time_frame>day before inclusion and day 1 to day 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart rate</measure>
    <time_frame>day before inclusion and day 1 to day 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Central venous pressure</measure>
    <time_frame>day before inclusion and day 1 to day 5</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sequential organ failure assessment (SOFA) score</measure>
    <time_frame>at ICU admission, at inclusion and day 1 to day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of need for catecholamine application</measure>
    <time_frame>28 days follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of need for mechanical ventilation</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of need for renal replacement therapy</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in intensive care unit (ICU)</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Systemic Inflammatory Response Syndrome</condition>
  <condition>Kidney Failure, Acute</condition>
  <arm_group>
    <arm_group_label>HCO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High cut-off filters HCO1100</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>conventional high-flux filters</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>continuous venovenous hemodialysis</intervention_name>
    <description>dialysate flow rate 35 ml/h/kg. Blood flow rate should be aimed at 200 ml/min, but not less than 150 ml/min. Bicarbonate- or lactate-buffered solutions will be used as dialysis fluids. Study dialyzers will be changed routinely every 24 h or earlier if the filter is obstructed by clotting.</description>
    <arm_group_label>HCO</arm_group_label>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Fulfilling at least two of the SIRS criteria as defined by the American College of
             Chest Physicians (ACCP)/Society of Critical Care Medicine (SCCM) Consensus Conference

          2. Having signs of renal dysfunction

          3. Requirement for catecholamine administration (norepinephrine or others)

          4. Acute Physiology And Chronic Health Evaluation (APACHE II) score at enrolment greater
             than or equal to 19 and less than or equal to 30

        Exclusion Criteria:

          1. Lack of written informed consent from patients or a legally authorized surrogate

          2. Duration of septic shock greater than 4 days

          3. Hypoproteinemia (characterized by serum albumin less than 18 g/l)

          4. End stage renal failure

          5. Known active malignancy

          6. Known human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus
             (HCV) infection

          7. Age younger than 18 years or older than 80 years

          8. Known pregnancy

          9. Immunosuppression after transplantation

         10. Participation in another clinical study

         11. Renal replacement therapy greater than 24 hours before randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Werner Beck, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Gambro Dialysatoren GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Leopold Franzens Universität Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik mit Schwerpunkt Nephrologie Charite, Campus Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité-Virchow Klinik</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Morgera S, Haase M, Kuss T, Vargas-Hein O, Zuckermann-Becker H, Melzer C, Krieg H, Wegner B, Bellomo R, Neumayer HH. Pilot study on the effects of high cutoff hemofiltration on the need for norepinephrine in septic patients with acute renal failure. Crit Care Med. 2006 Aug;34(8):2099-104.</citation>
    <PMID>16763508</PMID>
  </reference>
  <reference>
    <citation>Morgera S, Haase M, Rocktäschel J, Böhler T, von Heymann C, Vargas-Hein O, Krausch D, Zuckermann-Becker H, Müller JM, Kox WJ, Neumayer HH. High permeability haemofiltration improves peripheral blood mononuclear cell proliferation in septic patients with acute renal failure. Nephrol Dial Transplant. 2003 Dec;18(12):2570-6.</citation>
    <PMID>14605279</PMID>
  </reference>
  <reference>
    <citation>Morgera S, Rocktäschel J, Haase M, Lehmann C, von Heymann C, Ziemer S, Priem F, Hocher B, Göhl H, Kox WJ, Buder HW, Neumayer HH. Intermittent high permeability hemofiltration in septic patients with acute renal failure. Intensive Care Med. 2003 Nov;29(11):1989-95. Epub 2003 Sep 3.</citation>
    <PMID>12955174</PMID>
  </reference>
  <reference>
    <citation>Morgera S, Haase M, Rocktäschel J, Böhler T, Vargas-Hein O, Melzer C, Krausch D, Kox WJ, Baumann G, Beck W, Göhl H, Neumayer HH. Intermittent high-permeability hemofiltration modulates inflammatory response in septic patients with multiorgan failure. Nephron Clin Pract. 2003;94(3):c75-80.</citation>
    <PMID>12902634</PMID>
  </reference>
  <reference>
    <citation>Morgera S, Slowinski T, Melzer C, Sobottke V, Vargas-Hein O, Volk T, Zuckermann-Becker H, Wegner B, Müller JM, Baumann G, Kox WJ, Bellomo R, Neumayer HH. Renal replacement therapy with high-cutoff hemofilters: Impact of convection and diffusion on cytokine clearances and protein status. Am J Kidney Dis. 2004 Mar;43(3):444-53.</citation>
    <PMID>14981602</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2009</study_first_submitted>
  <study_first_submitted_qc>April 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2009</study_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Systemic Inflammatory Response Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

